North Carolina
Alzheimer's disease clinical trials in North Carolina
20 Alzheimer's disease studies are recruiting participants at sites in 9 cities across North Carolina as of November 16, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every North Carolina city with a recruiting study
Durham (6), Matthews (5), Morehead City (3), Chapel Hill (2), Charlotte (2), Greensboro (2), Raleigh (2), Monroe (1), Winston-Salem (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Recently updated studies in North Carolina
Basic details from each study's public record (the 12 most recently updated of 20). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Phase 3
- Ages 50 to 90
- All sexes
- Sponsor
- Hoffmann-La Roche
- Recruiting in
- Greensboro
- Registry record
- NCT07177352 · updated
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Recruiting in
- Matthews
- Registry record
- NCT05980949 · updated
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Recruiting in
- Morehead City
- Registry record
- NCT06937229 · updated
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
- Phase 2
- Ages 55 and older
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Recruiting in
- Charlotte · Matthews
- Registry record
- NCT06540833 · updated
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Recruiting in
- Morehead City
- Registry record
- NCT07011745 · updated
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
- Phase 1
- Ages 50 to 85
- All sexes
- Sponsor
- Eli Lilly and Company
- Recruiting in
- Durham
- Registry record
- NCT06297590 · updated
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
- Phase 3
- Ages 55 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Recruiting in
- Monroe
- Registry record
- NCT07602582 · updated
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Recruiting in
- Greensboro · Matthews · Morehead City
- Registry record
- NCT06585787 · updated
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
- Phase 2
- Ages 50 to 85
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Matthews
- Registry record
- NCT07033494 · updated
Wake Forest Alzheimer's Disease Clinical Core
- Observational
- Ages 55 and older
- All sexes
- Sponsor
- Wake Forest University Health Sciences
- Recruiting in
- Winston-Salem
- Registry record
- NCT03140865 · updated
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
- Phase 2
- Ages 55 to 90
- All sexes
- Sponsor
- Celgene
- Recruiting in
- Charlotte · Raleigh
- Registry record
- NCT06808984 · updated
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
- Phase 2
- Ages 50 and older
- All sexes
- Sponsor
- Duke University
- Recruiting in
- Durham
- Registry record
- NCT06041789 · updated
Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in North Carolina on ClinicalTrials.gov.
Ask about studies in North Carolina
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Clinical Trials for Alzheimer's Disease does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections